Project Grant R21AI193495
Award Date 9/19/25
Completion Date 8/31/26
Dollars Obligated $156K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $164,000.00 in funding to Albany Medical College to conduct research on specialized pro-resolving lipid mediators for developing systemic radiation countermeasures. The project aims to address the urgent and unmet clinical need to limit radiation-induced damage in the event of a nuclear incident. Specifically, the research will investigate how pro-resolving lipid...
- This Project Grant award of $157,000 was provided by the U.S. Department of Health and Human Services' National Institutes of Health (NIH) through the Trans-NIH Research Support program (CFDA 93.310). The funding supports the development of UTS-1401, a novel small molecule agent, as a medical countermeasure to mitigate hematopoietic acute radiation syndrome (H-ARS) following a radiation mass casualty event. The research, conducted by the collaborative partnership of Henry Ford Health and...
- The National Institutes of Health (NIH), through the Trans-NIH Research Support program (CFDA 93.310), awarded a $170,800 Project Grant to the New York Blood Center, Inc. to develop a radiation countermeasure that addresses sex-dependent radiation responses. The research aims to understand the mechanisms underlying sex-specific effects in regulating radiation response and to develop a novel radiation countermeasure that targets these differences. The project will determine the cellular and...
- This $586,619 Cooperative Agreement award was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) to Brigham & Women's Hospital Inc. The award supports research to develop a radiation medical countermeasure by harnessing trained immunity. Specifically, the project aims to determine if treating mice with CpG-DNA, a Toll-like receptor 9 agonist, can restore anti-microbial immune function and reduce delayed effects of acute radiation...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) aims to develop the pentapeptide MSP68 as a novel medical countermeasure to treat the deadly gastrointestinal acute radiation syndrome (GI-ARS). The $167,500 award to The Feinstein Institutes for Medical Research, a non-profit medical research organization, will fund a 2-year project to investigate MSP68 as a mitigator of GI-ARS and its ability to promote the...
- This federal Project Grant award of $160,125.00 from the Department of Health and Human Services' National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) is funding research to develop engineered microbes as medical countermeasures against gastrointestinal radiation damage. The primary objective is to assess the efficacy of a genetically modified Limosilactobacillus reuteri 6475 probiotic strain in accelerating the recovery of intestinal stem cells and the intestinal...
- This Project Grant award, valued at $158,500.00, was provided by the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310). The grant supports research to develop a novel, non-pharmacological strategy to mitigate radiation-induced cardiotoxicity, which can manifest in survivors of a radiological or nuclear incident. The primary awardee, Trustees of Indiana University (doing business as Indiana University Indianapolis), will use the funding to further...
- This Project Grant award from the National Institutes of Health's (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $157,500 to the University of California, Los Angeles (UCLA) to develop and test new analogues of the ER-beta agonist DPN as potential medical radiation countermeasures. The research aims to create compounds with improved oral bioavailability that could help mitigate radiation-induced injuries to the bone marrow, gastrointestinal, respiratory, and cardiovascular...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $159,075 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The Ohio State University. The grant, titled "VALIDATION OF MIRAD ASSAY AS A BIODOSIMETRY TOOL FOR RADIOLOGICAL/NUCLEAR TRIAGE APPLICATIONS IN PEDIATRIC AND GERIATRIC POPULATION", aims to develop and validate a rapid diagnostic tool for estimating radiation exposure levels in victims of...
- This $157,400 Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) supports the development of an effective medical countermeasure against gastrointestinal acute radiation syndrome (GI-ARS). The project aims to establish the efficacy of certain biocompatible amphiphilic block copolymers, developed by Maroon Biotech Corp, in increasing 10-day and 30-day survival rates as well as preserving gut barrier function in a...